Handling Missing Data in a Duloxetine Population Pharmacokinetic/Pharmacodynamic Model – Imputation Methods and Selection Models

[1]  Ivelina Gueorguieva,et al.  Population pharmacokinetic/pharmacodynamic models for duloxetine in the treatment of diabetic peripheral neuropathic pain , 2013, European journal of pain.

[2]  M. Heathman,et al.  Population Pharmacokinetics of Orally Administered Duloxetine in Patients , 2012, Clinical pharmacokinetics.

[3]  R T O'Neill,et al.  The Prevention and Treatment of Missing Data in Clinical Trials: An FDA Perspective on the Importance of Dealing With It , 2012, Clinical pharmacology and therapeutics.

[4]  An Vermeulen,et al.  Structural Models Describing Placebo Treatment Effects in Schizophrenia and Other Neuropsychiatric Disorders , 2011, Clinical pharmacokinetics.

[5]  S. Bongardt,et al.  Efficacy and Safety of Lacosamide in Diabetic Neuropathic Pain: An 18-week Double-blind Placebo-controlled Trial of Fixed-dose Regimens , 2009, The Clinical journal of pain.

[6]  M. Man-Son-Hing,et al.  Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review , 2009, Open medicine : a peer-reviewed, independent, open-access journal.

[7]  R. Gomeni,et al.  Modelling placebo response in depression trials using a longitudinal model with informative dropout. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[8]  P. Lane.  Handling drop‐out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches , 2008, Pharmaceutical statistics.

[9]  L. Hunt,et al.  Missing Data in Clinical Studies , 2007 .

[10]  J. Wernicke,et al.  A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain , 2006, Neurology.

[11]  Smriti Iyengar,et al.  A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. , 2005, Pain medicine.

[12]  M. Detke,et al.  Duloxetine vs. placebo in patients with painful diabetic neuropathy , 2005, Pain.

[13]  E. Whalen,et al.  Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens , 2005, Pain.

[14]  Jack A. Cook,et al.  The Use of Clinical Trial Simulation to Support Dose Selection: Application to Development of a New Treatment for Chronic Neuropathic Pain , 2003, Pharmaceutical Research.

[15]  Geert Molenberghs,et al.  Assessing and interpreting treatment effects in longitudinal clinical trials with missing data , 2003, Biological Psychiatry.

[16]  Mark E. Sale,et al.  A Joint Model for Nonlinear Longitudinal Data with Informative Dropout , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[17]  D. Fairclough.  Design and analysis of quality of life studies in clinical trials , 2002, Quality of Life Research.

[18]  A Lawrence Gould,et al.  COMPARISON OF ALTERNATIVE STRATEGIES FOR ANALYSIS OF LONGITUDINAL TRIALS WITH DROPOUTS , 2002, Journal of biopharmaceutical statistics.

[19]  J. Farrar,et al.  Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale , 2001, PAIN.

[20]  James Lindsey.  DROPOUTS IN LONGITUDINAL STUDIES: DEFINITIONS AND MODELS , 2000, Journal of biopharmaceutical statistics.

[21]  Andrew Thomas,et al.  WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility , 2000, Stat. Comput..

[22]  J. Schafer.  Multiple imputation: a primer , 1999, Statistical methods in medical research.

[23]  Adrian Dunne,et al.  Analysis of Nonrandomly Censored Ordered Categorical Longitudinal Data from Analgesic Trials , 1997 .

[24]  D. Spiegelhalter,et al.  Bayesian Analysis of Realistically Complex Models , 1996 .

[25]  Peter J. Diggle,et al.  Testing for random dropouts in repeated measurement data. , 1989 .

[26]  M. Heathman,et al.  Erratum to: Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation , 2009 .

[27]  R. Woolson,et al.  Substance Abuse Treatment, Prevention, and Policy a Comparison of Missing Data Methods for Hypothesis Tests of the Treatment Effect in Substance Abuse Clinical Trials: a Monte-carlo Simulation Study , 2007 .

[28]  O Siddiqui,et al.  A comparison of the random-effects pattern mixture model with last-observation-carried-forward (LOCF) analysis in longitudinal clinical trials with dropouts. , 1998, Journal of biopharmaceutical statistics.

[29]  P. Diggle,et al.  Testing for random dropouts in repeated measurement data. , 1989, Biometrics.